On Friday, Shares of JetBlue Airways Corporation (NASDAQ:JBLU), gained 1.26% to $21.76, hitting its highest level.
JetBlue Airways, declared that it will webcast a presentation at the Bank of America Merrill Lynch 2015 Transportation Conference on May 14, 2015.
The presentation is planned to start at about 11:20 a.m. ET.
JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 13 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 EMBRAER 190 aircrafts.
Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), inclined 4.11% to $9.11, during its last trading session.
ARIAD Pharmaceuticals, stated financial results for the first quarter of 2015, counting revenue from sales of Iclusig® (ponatinib). The Company also offered an update on corporate developments.
2015 First Quarter Financial Results
- Net product revenues from sales of Iclusig were $23.9 million for the quarter ended March 31, 2015, an enhance of 12% as compared to the fourth quarter of 2014. Net product revenues for the first quarter comprise Iclusig revenues of $18.7 million in the U.S. and $5.2 million in Europe. U.S. sales of Iclusig raised 10% from the fourth quarter of 2014 to the first quarter of 2015, and European sales raised 18%, net of the impact of changes in foreign exchange rates for the first quarter.
- In the quarter ended March 31, 2015, we transitioned to the sell-in method for recognition of product revenues in the U.S., resulting in a one-time addition to revenue of about $1.2 million for the first quarter.
- Shipments of Iclusig to patients in France were $1.9 million for the first quarter of 2015. Cumulative total shipments in France, taking into account the effects of foreign exchange, totaled $18.3 million through March 31, 2015. We will record revenue related to cumulative shipments in France upon completion of pricing and reimbursement negotiations in France, net of any amounts that will be refunded to the French health authorities as a result of such negotiations, which we anticipate will be accomplished in mid-2015.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
At the end of Friday’s trade, Shares of Liberty Global plc (NASDAQ:LBTYK), lost -2.94% to $48.82.
Liberty Global, declared financial and operating results for the three months ended March 31, 2015.
Subscriber Statistics
At March 31, 2015, the company offered a total of 56.0 million subscription services (“RGUs”) to the 27.3 million unique customers across its cable footprint of 52.1 million homes passed. These services comprised of 24.2 million video, 17.4 million broadband internet and 14.4 million telephony subscriptions. During the first quarter of 2015, the company raised its RGUs by 80,000, primarily driven by 68,000 organic RGU additions. The company ended the quarter with a bundling ratio of 2.05 RGUs per customer and a total of 16.6 million bundled customers, or 61% of its total customer base.
During the past several quarters, the company made substantial investments in product development and its superior network to deliver innovative products and services, counting superfast broadband, Horizon TV, Horizon Go, WiFi and MyPrime, that differentiate it from its competitors. These and other improvements underpinned its price enhances, which were implemented in 12 of its markets in Q1 2015, and contributed to its Q1 FX-neutral customer ARPU enhance of 5% year-over-year. The enhances were implemented successfully in markets such as the U.K. and Belgium.
During Q1, the company practiced lower sales and elevated churn, which tempered its Q1 2015 organic RGU additions to 68,000 as contrast to 345,000 RGU additions in Q1 2014. As the company look forward, it is confident that its compelling and innovative products will gain further traction, and expect a noteworthy enhance in the average level of quarterly organic RGU additions for the rest of the year.
Liberty Global plc, together with its auxiliaries, provides video, broadband Internet, fixed-line telephony, and mobile services in Europe, Chile, Puerto Rico, and internationally. The company offers various residential services, counting video services comprising basic and premium programming, which can be viewed on the television and Internet connected devices; electronic programming guide, high definition (HD) channels, digital video recorder (DVR), and HD DVR services; video-on-demand, set-top boxes, pay-per-view programming, and programming in three-dimensional format services, in addition to television applications that allow access to programming on laptops, smartphones, and tablets; and entertainment, sports, movies, documentaries, lifestyles, news, adult, children, and ethnic and foreign channels.
Finally, Aeterna Zentaris Inc. (NASDAQ:AEZS), ended its last trade with -3.24% loss, and closed at $0.51.
Aeterna Zentaris, stated financial and operating results for the first quarter ended March 31, 2015.
Research and development (“R&D”) costs, were $4.5 million for the three-month period ended March 31, 2015, contrast to $5.8 million for the same period in 2014. This decrease is attributable to lower comparative employee compensation and benefits costs, facilities rent and maintenance in addition to other costs. A substantial portion of this decrease is due to the realization of cost savings in connection with the Company’s global resource optimization program in addition to the lower comparative exchange rate of the EUR against the US dollar. This decrease was partly compensated by higher third-party costs, mostly related to the Company’s ZoptEC Phase 3 clinical trial in endometrial cancer.
Selling, general and administrative (“SG&A”) expenses were $5.1 million for the three-month period ended March 31, 2015, as contrast to $2.4 million for the same period in 2014. This enhance is attributable to the Company’s raised selling activities, associated with the co-promotion efforts related to EstroGel®, with $1.1 million of first quarter 2015 expenses being related to higher costs associated with Aeterna Zentaris’ contracted sales force and its own sales and marketing staff. Additionally, about $0.8 million of the quarter-over-quarter enhance is attributable to transaction costs incurred in connection with the completion of the March 2015 Offering. Other enhances are attributable in large part to lower comparative foreign exchange gains.
Net loss for the three-month period ended March 31, 2015 was $9.7 million, or $0.13 per basic and diluted share, contrast to $4.4 million, or $0.08 per basic and diluted share, for the same period in 2014. This enhance in net loss is due largely to higher comparative SG&A expenses and to higher comparative net finance costs, partially offset by lower comparative R&D costs.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
